Products for Research Use Only

JNJ-10198409

CAT: 0804-HY-W011266-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W011266-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC50=2 nM) . It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM) [1][2].
CAS Number
627518-40-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PDGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jnj-10198409.html
Purity
99.58
Solubility
DMSO : 83.33 mg/mL (ultrasonic)
Smiles
COC1=CC2=C(C=C1OC)CC3=C2NN=C3NC4=CC=CC(F)=C4
Molecular Formula
C18H16FN3O2
Molecular Weight
325.34
Precautions
H302, H315, H319, H335
References & Citations
[1]D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4 (8) :1198-204.|[2]Ho CY, et al. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl) phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem. 2005 Dec 29;48 (26) :8163-73.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDGFRα; PDGFRβ